Carl Ola Landgren, MD, PhD

Panelists discuss evolving approaches to maintenance therapy in newly diagnosed multiple myeloma, focusing on balancing survival benefits with tolerability. They also review the latest data from the AURIGA trial evaluating daratumumab and lenalidomide maintenance.

Panelists discuss the factors influencing the choice between isatuximab and daratumumab for induction therapy in transplant-eligible newly diagnosed multiple myeloma, as well as the role of dara-based quadruplet regimens as the standard of care and considerations for triplet regimens in specific patient populations.

Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.